TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Amur Minerals ( (GB:CRTX) ) is now available.
CRISM Therapeutics Corporation has received regulatory and ethical approval to initiate a Phase 2 clinical trial of its irinotecan-ChemoSeed in patients with surgically resectable glioblastoma. This approval marks a significant milestone, allowing the company to begin the trial in Q1 2026 at leading UK neuro-oncology centers. The trial aims to assess the safety and efficacy of the ChemoSeed platform, which delivers sustained-release irinotecan directly into the tumor site, potentially offering a more effective treatment with fewer side effects. This development is expected to pave the way for future marketing authorizations and commercial advancements.
More about Amur Minerals
CRISM Therapeutics Corporation is a UK-based clinical-stage drug delivery company specializing in the localized and sustained delivery of chemotherapy drugs. The company’s lead product, ChemoSeed, is designed to improve the clinical performance of cancer treatments for solid tumors by delivering chemotherapy drugs directly into the tumor or resection margin, particularly in cases of glioblastoma.
Average Trading Volume: 57,969
Technical Sentiment Signal: Sell
Current Market Cap: £4.2M
Learn more about CRTX stock on TipRanks’ Stock Analysis page.